Prevention of mother-to-child transmission of HIV Type 1: The role of neonatal and infant prophylaxis

Expert Review of Anti-Infective Therapy

Volumn 13, Issue 2, 2015, Pages 169-181

  Hurst, Stacey A ^a   Appelgren, Kristie E ^a   Kourtis, Athena P ^a  

^a NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

Author keywords

breastfeeding; HIV; infant; mother; neonatal; perinatal; prevention; prophylaxis; transmission

Indexed keywords

EMTRICITABINE; HYPERIMMUNE GLOBULIN; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PLACEBO; TENOFOVIR; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ANEMIA; BREAST FEEDING; CD4 LYMPHOCYTE COUNT; DISEASE TRANSMISSION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; GESTATIONAL AGE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPERLACTATEMIA; IMMUNOPROPHYLAXIS; INFANT FEEDING; INFECTION PREVENTION; INTRAPARTUM CARE; MEDICATION COMPLIANCE; META ANALYSIS (TOPIC); NEUTROPENIA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PREVENTION OF MOTHER TO CHILD TRANSMISSION; PUERPERIUM; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; TREATMENT WITHDRAWAL; VACCINATION; DRUG EFFECTS; FEMALE; HIV INFECTIONS; INFANT; MOTHER; NEWBORN; PHYSIOLOGY; PRE-EXPOSURE PROPHYLAXIS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREVENTION AND CONTROL; TRANSMISSION; VERTICAL TRANSMISSION;

ANTI-HIV AGENTS; BREAST FEEDING; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFANT; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MOTHERS; PRE-EXPOSURE PROPHYLAXIS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS;

EID: 84937140922     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.2015.999667     Document Type: Review

References (85)

1. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommendations for a public health approach. Geneva, World Health Organization; 2013. Available from: http://www.who.int/hiv/pub/guidelines/arv2013/download/en/[Accessed 7 March 2014]
2. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. Available from: http://aidsinfo.nih. gov/contentfiles/lvguidelines/PerinatalGL.pdf [Accessed 3 May 2014]
3. Centers for Disease Control and Prevention. HIV Surveillance Report, 2011. Volume 23 Available from: http://www.cdc.gov/hiv/topics/surveillance/resources/reports/Published February 2013 [Accessed 24 June 2014]
4. UNAIDS. Global Report: UNAIDS report on the global AIDS epidemic 2013. Available from: http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2013/gr2013/unaids-global-report-2013-en.pdf [Accessed 4 May 2014]
5. Kourtis AP, Bulterys M. Mother-to-child transmission of HIV: pathogenesis, mechanisms and pathways. Clin Perinatol 2010;37(4):721-37; vii
6. Mandelbrot L, Burgard M, Teglas JP, et al. Frequent detection of HIV-1 in the gastric aspirates of neonates born to HIV-infected mothers. AIDS 1999;13(15):2143-9
7. Zack JA, Haislip AM, Krogstad P, Chen IS. Incompletely reverse-transcribed human immunodeficiency virus type 1 genomes in quiescent cells can function as intermediates in the retroviral life cycle. J Virol 1992; 66(3):1717-25
8. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994; 331(18):1173-80
9. Centers for Disease Control (CDC). Recommendations of the U.S. Public Health Service Task Force on the use of zidovudine to reduce perinatal transmission of human immunodeficiency virus. MMWR Recomm Rep 1994;43(RR-11):1-20
10. Centers for Disease Control (CDC). Public Health Service Task Force recommendations for the use of antiretroviral drugs in pregnant women infected with HIV-1 for maternal health and for reducing perinatal HIV-1 transmission in the United States. Centers for Disease Control and Prevention. MMWR Recomm Rep 1998;47(RR-2):1-30
11. Dabis F, Mandelbrot L, Msellati P, Van de Perre P. Zidovudine to decrease mother-to-child transmission of HIV-1: is it good for developing countries? AIDS 1995; 9(2):204-6
12. Shaffer N, Chuachoowong R, Mock PA, et al. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial. Bangkok Collaborative Perinatal HIV Transmission Study Group. Lancet 1999;353(9155): 773-80
13. Dabis F, Msellati P, Meda N, et al. 6-month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Cote d'Ivoire and Burkina Faso: a double-blind placebocontrolled multicentre trial. DITRAME Study Group. DIminution de la Transmission Mere-Enfant. Lancet 1999; 353(9155):786-92
14. Wiktor SZ, Ekpini E, Karon JM, et al. Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Cote d'Ivoire: a randomised trial. Lancet 1999;353(9155):781-5
15. Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999; 354(9181):795-802
16. Petra Study Team. Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra study): a randomised, double-blind, placebo-controlled trial. Lancet 2002;359(9313):1178-86
17. Jackson JB, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. Lancet 2003;362(9387):859-68
18. Eshleman SH, Mracna M, Guay LA, et al. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS 2001;15(15):1951-7
19. McIntyre JA, Hopley M, Moodley D, et al. Efficacy of short-course AZT plus 3TC to reduce nevirapine resistance in the prevention of mother-to-child HIV transmission: a randomized clinical trial. PLoS Med 2009;6(10):e1000172
20. Farr SL, Nelson JA, Ng'ombe TJ, et al. Addition of 7 days of zidovudine plus lamivudine to peripartum single-dose nevirapine effectively reduces nevirapine resistance postpartum in HIV-infected mothers in Malawi. J Acquir Immune Defic Syndr 2010;54(5):515-23
21. Chi BH, Sinkala M, Mbewe F, et al. Single-dose tenofovir and emtricitabine for reduction of viral resistance to non-nucleoside reverse transcriptase inhibitor drugs in women given intrapartum nevirapine for perinatal HIV prevention: an open-label randomised trial. Lancet 2007;370(9600):1698-705
22. Lallemant M, Jourdain G, Le Coeur S, et al. A trial of shortened zidovudine regimens to prevent mother-to-child transmission of human immunodeficiency virus type 1. Perinatal HIV Prevention Trial (Thailand) Investigators. N Engl J Med 2000;343(14):982-91
23. Lallemant M, Jourdain G, Le Coeur S, et al. Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N Engl J Med 2004;351(3): 217-28
24. Dorenbaum A, Cunningham CK, Gelber RD, et al. Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized trial. JAMA 2002;288(2):189-98
25. Wade NA, Birkhead GS, Warren BL, et al. Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. N Engl J Med 1998;339(20):1409-14
26. Wade NA. Short courses of zidovudine and perinatal transmission of HIV. N Engl J Med 1999;340(13):1042-3
27. Nielsen-Saines K, Watts DH, Veloso VG, et al. Three postpartum antiretroviral regimens to prevent intrapartum HIV infection. N Engl J Med 2012;366(25): 2368-79
28. Taha TE, Kumwenda NI, Gibbons A, et al. Short postexposure prophylaxis in newborn babies to reduce mother-to-child transmission of HIV-1: NVAZ randomised clinical trial. Lancet 2003;362(9391):1171-7
29. Taha TE, Kumwenda NI, Hoover DR, et al. Nevirapine and zidovudine at birth to reduce perinatal transmission of HIV in an African setting: a randomized controlled trial. JAMA 2004;292(2):202-9
30. Gray GE, Urban M, Chersich MF, et al. A randomized trial of two postexposure prophylaxis regimens to reduce mother-to-child HIV-1 transmission in infants of untreated mothers. AIDS 2005; 19(12):1289-97
31. Chasela CS, Hudgens MG, Jamieson DJ, et al. Maternal or infant antiretroviral drugs to reduce HIV-1 transmission. N Engl J Med 2010;362(24):2271-81
32. Thomas TK, Masaba R, Borkowf CB, et al. Triple-antiretroviral prophylaxis to prevent mother-to-child HIV transmission through breastfeeding-the Kisumu Breastfeeding Study, Kenya: a clinical trial. PLoS Med 2011;8(3):e1001015
33. Kilewo C, Karlsson K, Ngarina M, et al. Prevention of mother-to-child transmission of HIV-1 through breastfeeding by treating mothers with triple antiretroviral therapy in Dar es Salaam, Tanzania: the Mitra Plus study. J Acquir Immune Defic Syndr 2009; 52(3):406-16
34. Kesho Bora Study Group. de Vincenzi I. Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial. Lancet Infect Dis 2011; 11(3):171-80
35. Shapiro RL, Hughes MD, Ogwu A, et al. Antiretroviral regimens in pregnancy and breast-feeding in Botswana. N Engl J Med 2010;362(24):2282-94
36. Shapiro RL, Thior I, Gilbert PB, et al. Maternal single-dose nevirapine versus placebo as part of an antiretroviral strategy to prevent mother-to-child HIV transmission in Botswana. AIDS 2006; 20(9):1281-8
37. Thior I, Lockman S, Smeaton LM, et al. Breastfeeding plus infant zidovudine prophylaxis for 6 months vs formula feeding plus infant zidovudine for 1 month to reduce mother-to-child HIV transmission in Botswana: a randomized trial: the Mashi Study. JAMA 2006;296(7):794-805
38. Six Week Extended-Dose Nevirapine Study Team. Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials. Lancet 2008; 372(9635):300-13
39. Kumwenda NI, Hoover DR, Mofenson LM, et al. Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission. N Engl J Med 2008;359(2):119-29
40. Taha TE, Li Q, Hoover DR, et al. Postexposure prophylaxis of breastfeeding HIV-exposed infants with antiretroviral drugs to age 14 weeks: updated efficacy results of the PEPI-Malawi trial. J Acquir Immune Defic Syndr 2011;57(4):319-25
41. Kilewo C, Karlsson K, Massawe A, et al. Prevention of mother-to-child transmission of HIV-1 through breast-feeding by treating infants prophylactically with lamivudine in Dar es Salaam, Tanzania: the Mitra Study. J Acquir Immune Defic Syndr 2008;48(3): 315-23
42. Jamieson DJ, Chasela CS, Hudgens MG, et al. Maternal and infant antiretroviral regimens to prevent postnatal HIV-1 transmission: 48-week follow-up of the BAN randomised controlled trial. Lancet 2012;379(9835):2449-58
43. Coovadia HM, Brown ER, Fowler MG, et al. Efficacy and safety of an extended nevirapine regimen in infant children of breastfeeding mothers with HIV-1 infection for prevention of postnatal HIV-1 transmission (HPTN 046): a randomised, double-blind, placebo-controlled trial. Lancet 2012; 379(9812):221-8
44. Fowler MG, Coovadia H, Herron CM, et al. Efficacy and safety of an extended nevirapine regimen in infants of breastfeeding mothers with HIV-1 infection for prevention of HIV-1 transmission (HPTN 046): 18-month results of a randomized, double-blind, placebo-controlled trial. J Acquir Immune Defic Syndr 2014;65(3):366-74
45. Kankasa C, Nagot N, Meda N, et al. Infant Lopinavir/ritonavir versus 3TC to prevent postnatal HIV-1 transmission: the ANRS 12174 Trial [abstract 70]. 2014 Conference on Retroviruses and Opportunistic Infections; 3-6 March 2014; Boston, MA
46. World Health Organization. Guidelines on HIV and infant feeding 2010. Principles and recommendations for infant feeding in the context of HIV and a summary of evidence. Available from: www.who.int/maternal-child-adolescent/documents/9789241599535/en/[Accessed 7 March 2014]
47. Evaluating Strategies to Reduce Mother-to-Child Transmission of HIV Infection in Resource-Limited Countries (PROMISE). Available from: http://clinicaltrials.gov/ct2/show/NCT01061151 [Accessed 5 May 2014]
48. Evaluating Strategies to Reduce Mother-to-Child Transmission of HIV Infection in Populations Using Formula Feeding (PROMISE). Available from: http://clinicaltrials.gov/ct2/show/NCT01253538 [Accessed 5 May 2014]
49. Examining Benefits of HAART Continuation in Postpartum Mothers. Available from: http://clinicaltrials.gov/ct2/show/NCT00955968 [Accessed 5 May 2014]
50. Study of Effects of Tenofovir on Bone Health and Kidneys During Pregnancy and Breastfeeding. Available from: http://clinicaltrials.gov/ct2/show/NCT01066858 [Accessed 5 May 2014]
51. Taylor GP, Clayden P, Dhar J, et al. British HIV Association guidelines for the management of HIV infection in pregnant women 2012. HIV Med 2012;13(Suppl 2): 87-157
52. Ferguson W, Goode M, Walsh A, et al. Evaluation of 4 weeks' neonatal antiretroviral prophylaxis as a component of a prevention of mother-to-child transmission program in a resource-rich setting. Pediatr Infect Dis J 2011;30(5):408-12
53. Aebi-Popp K, Mulcahy F, Rudin C, et al. National Guidelines for the prevention of mother-to-child transmission of HIV across Europe-how do countries differ? Eur J Public Health 2013;23(6):1053-8
54. Mugabo P, Els I, Smith J, et al. Nevirapine plasma concentrations in premature infants exposed to single-dose nevirapine for prevention of mother-to-child transmission of HIV-1. S Afr Med J 2011;101(9):655-8
55. Havens PL, Mofenson LM. Evaluation and management of the infant exposed to HIV-1 in the United States. Pediatrics 2009;123(1):175-87
56. National Institute of Allergy and Infectious Diseases. "Mississippi Baby" Now Has Detectable HIV, Researchers Find. 10 July 2014. Available from: www.niaid.nih.gov/news/newsreleases/2014 [Accessed 1 August 2014]
57. Persaud D, Gay H, Ziemniak C, et al. Absence of detectable HIV-1 viremia after treatment cessation in an infant. N Engl J Med 2013;369(19):1828-35
58. Very Early Intensive Treatment of HIV-Infected Infants to Achieve HIV Remission. Available from: www. clinicaltrials.gov/ct2/show/NCT02140255 [Accessed 2 June 2014]
59. Alimenti A, Burdge DR, Ogilvie GS, et al. Lactic acidemia in human immunodeficiency virus-uninfected infants exposed to perinatal antiretroviral therapy. Pediatr Infect Dis J 2003;22(9):782-9
60. Noguera A, Fortuny C, Munoz-Almagro C, et al. Hyperlactatemia in human immunodeficiency virus-uninfected infants who are exposed to antiretrovirals. Pediatrics 2004;114(5):e598-603
61. Ekouevi DK, Toure R, Becquet R, et al. Serum lactate levels in infants exposed peripartum to antiretroviral agents to prevent mother-to-child transmission of HIV: agence Nationale de Recherches Sur le SIDA et les Hepatites Virales 1209 study, Abidjan, Ivory Coast. Pediatrics 2006; 118(4):e1071-7
62. Barret B, Tardieu M, Rustin P, et al. Persistent mitochondrial dysfunction in HIV-1-exposed but uninfected infants: clinical screening in a large prospective cohort. AIDS 2003;17(12):1769-85
63. Blanche S, Tardieu M, Rustin P, et al. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet 1999; 354(9184):1084-9
64. Bulterys M, Nesheim S, Abrams EJ, et al. Lack of evidence of mitochondrial dysfunction in the offspring of HIV-infected women. Retrospective review of perinatal exposure to antiretroviral drugs in the Perinatal AIDS Collaborative Transmission Study. Ann N Y Acad Sci 2000;918:212-21
65. Nucleoside exposure in the children of HIV-infected women receiving antiretroviral drugs: absence of clear evidence for mitochondrial disease in children who died before 5 years of age in five United States cohorts. J Acquir Immune Defic Syndr 2000;25(3):261-8
66. European Collaborative Study. Exposure to antiretroviral therapy in utero or early life: the health of uninfected children born to HIV-infected women. J Acquir Immune Defic Syndr 2003;32(4):380-7
67. Mirochnick M, Taha T, Kreitchmann R, et al. Pharmacokinetics and safety of tenofovir in HIV-infected women during labor and their infants during the first week of life. J Acquir Immune Defic Syndr 2014; 65(1):33-41
68. Klein R, Struble K. Kaletra (lopinavir/ritonavir) Oral Solution label changes related to toxicity in preterm neonates. 2011. Available from: www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/HIVandAIDSActivities/ucm244639.htm [Accessed 23 June 2014]
69. Simon A, Warszawski J, Kariyawasam D, et al. Association of prenatal and postnatal exposure to lopinavir-ritonavir and adrenal dysfunction among uninfected infants of HIV-infected mothers. JAMA 2011;306(1): 70-8
70. Mahy M, Stover J, Kiragu K, et al. What will it take to achieve virtual elimination of mother-to-child transmission of HIV? An assessment of current progress and future needs. Sex Tranms Infect 2010;86(Suppl 2): ii48-55
71. Nachega JB, Uthman OA, Anderson J, et al. Adherence to antiretroviral therapy during and after pregnancy in low-income, middle-income, and high-income countries: a systematic review and meta-analysis. AIDS 2012;26(16):2039-52
72. Demas PA, Webber MP, Schoenbaum EE, et al. Maternal adherence to the zidovudine regimen for HIV-exposed infants to prevent HIV infection: a preliminary study. Pediatrics 2002;110(3):e35
73. Mofenson LM. Prevention of mother-to-child HIV-1 transmission - why we still need a preventive HIV immunization strategy. J Acquir Immune Defic Syndr 2011;58(4):359-62
74. McFarland EJ, Johnson DC, Muresan P, et al. HIV-1 vaccine induced immune responses in newborns of HIV-1 infected mothers. AIDS 2006;20(11):1481-9
75. Kintu K, Andrew P, Musoke P, et al. Feasibility and safety of ALVAC-HIV vCP1521 vaccine in HIV-exposed infants in Uganda: results from the first HIV vaccine trial in infants in Africa. J Acquir Immune Defic Syndr 2013;63(1):1-8
76. Kaleebu P, Njai HF, Wang L, et al. Immunogenicity of ALVAC-HIV vCP1521 in infants of HIV-1-infected women in Uganda (HPTN 027): the first pediatric HIV vaccine trial in Africa. J Acquir Immune Defic Syndr 2014;65(3): 268-77
77. Afolabi MO, Ndure J, Drammeh A, et al. A phase I randomized clinical trial of candidate human immunodeficiency virus type 1 vaccine MVA.HIVA administered to Gambian infants. PLoS One 2013;8(10): e78289
78. Rerks-Ngarm S, Pitisuttithum P, Kaikungwal J, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009;361(23):2209-20
79. Onyango-Makumbi C, Omer SB, Mubiru M, et al. Safety and efficacy of HIV hyperimmune globulin for prevention of mother-to-child HIV transmission in HIV-1-infected pregnant women and their infants in Kampala, Uganda (HIVIGLOB/NVP STUDY). J Acquir Immune Defic Syndr 2011;58(4):399-407
80. Corti D, Lanzavecchia A. Broadly neutralizing antiviral antibodies. Annu Rev Immunol 2013;31:705-42
81. Voronin Y, Mofenson LM, Cunningham CK, et al. HIV monoclonal antibodies: a new opportunity to further reduce mother-to-child HIV transmission. PLoS Med 2014;11(4):e1001616
82. Evaluating the Safety and Pharmacokinetics of VRC01, a Potent Anti-HIV Neutralizing Monoclonal Antibody, in HIV-1-Exposed Infants. Available from: www.clinicaltrials. gov/ct2/show/NCT02256631 [Accessed 22 October 2014]
83. Gompels UA, Larke N, Sanz-Ramos M, et al. Human cytomegalovirus infant infection adversely affects growth and development in maternally HIV-exposed and unexposed infants in Zambia. Clin Infect Dis 2012;54(3):434-42
84. Kourtis AP, Ibegbu CC, Wiener J, et al. Role of intestinal mucosal integrity in HIV transmission to infants through breastfeeding: the BAN study. J Infect Dis 2013; 208(4):653-61
85. World Health Organization. Global HIV/AIDS response: epidemic update and health sector progress towards universal access: progress report 2011. Available from: www. who.int/hiv/pub/progress-report2011/en/[Accessed 24 June 2014]